Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Hepatitis Clinical Trials

A listing of Hepatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (311) clinical trials

Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B

The purpose of this study is to evaluate the safety and efficacy of Domestic Tenofovir Disoproxil Fumarate Tablets in Chinese patients with hepatitis B ,compared with Tenofovir Disoproxil Fumarate Tablets of Gilead.

Phase N/A

Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)

Open-labelled pilot clinical trial of Zepatier (MK-5172 and MK-8742/Grazoprevir + Elbasvir) in 10 HCV-negative subjects receiving a heart transplant from a HCV-positive donor. Eligible subjects will receive a heart transplant from a deceased-donor with genotype 1 or 4 HCV, and then will receive 12 weeks of Zepatier after heart transplantation ...

Phase

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)

Patients who receive direct-acting anti-HCV treatment will be prospectively studied during 2-year period. All patients have HCV/HBV co-infection. The inclusion/exclusion criteria and the follow up plan will be listed in following part.

Phase

Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF

Tenofovir disoproxil fumarate(TDF) have been associated with renal toxicity and reduced bone mineral density. Tenofovir alafenamide(TAF) is a novel tenofovir prodrug that reduces tenofovir plasma concentrations by 90%, thereby decreasing off-target side-effects. The investigators aimed to assess whether efficacy, safety, and tolerability were non-inferior in participants switched to TAF versus ...

Phase

Switching Regimen in Treating Cirrhotic HCV GT1b Subjects

This is a prospective, randomized study to evaluate the efficacy and safety of switching treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with CHC genotype 1b infection, who are interferon/ribavirin-intolerant.

Phase

Plasma Exchange Combination of Immunosuppressive Regimens for Auto-immune Hepatitis

An open-label,pilot study to evaluate the efficacy and safety of plasma exchange combination of immunosuppressive regimens, for the remission of autoimmune hepatitis (AIH).

Phase N/A

Transplanting Hepatitis C Positive Thoracic Organs

This is an open label pilot study transplanting thoracic organs from Hepatitis C positive donors into HCV uninfected recipients at Brigham and Women's Hospital. Heart and lung transplant participants will be stratified into two different study arms depending on whether the donor of the thoracic organ was HCV nucleic acid ...

Phase

Counseling for HIV and STIs Screening

The study will be presented to clients, who will be asked to formally consent to participate. Clients residing or working in northern Thailand and able to communicate with the counselor will be eligible. Foreigners staying in Thailand for vacation or retirement will be excluded, except if presenting together with their ...

Phase N/A

ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

The purpose of this study is to evaluate the safety and initial effectiveness of MRI-guided focused ultrasound thermal ablation of a designated area in the brain of patients suffering from movement disorder symptoms: FUS under MRI-guidance and MRI-based thermometry can be safely delivered to patients suffering from treatment-refractory movement disorders ...

Phase N/A

Patients are needed to participate in a clinical research study for the treatment of Liver Disease Chronic, Hepatitis B Virus

Intervention: Serological markers of HBV will be assessed prospectively in consecutive non-cirrhotic liver disease or cirrhotic patients. Seronegative patients willing to participate will sign a written informed consent and will receive four doses of 20 g Fendrix at 0,1, 2 and 6 months. Antibodies against HBV superficial antigen (anti-HBs) will ...

Phase N/A